Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B（CHB）. The objective of the ...Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B（CHB）. The objective of the present study was to compare the efficacy and safety of pegylated interferon（Peg-IFN） alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone（1.5 μg/kg once weekly） or Peg-IFN alpha-2b plus adefovir（10 mg daily） for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30（36.7%） patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31（25.8%） in the monotherapy group（P=0.36）. In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group（76.7% vs. 29.0%, P〈0.001）. Thyroid dysfunction was more frequent in the combination group than in the monotherapy group（P〈0.05）. In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function.展开更多
OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin＇s lymphoma （DLBCL）.METHODS From January 2003 to July ...OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin＇s lymphoma （DLBCL）.METHODS From January 2003 to July 2008, 51 patients received CHOP-like chemotherapy （cyclophosphamide 750 mg/m2, epirubicin 80 mg/m2, vindesine 2.8 mg/m2 on day 1, and prednisolone 100 mg/day on day 1 to day 5）. Thirty-one patients received CHOPR-like treatment （rituximab 375 mg/m2 1 day before CHOP-like chemotherapy）. Twenty patients received CHOP-like regimen in combination with peginterferon （pegIFN） （1μg/kg on day 5） and rituximab （on day 6）.RESULTS -The CR （complete remission） rate in the CHOPR-like （with or without pegIFN） group and in the CHOP-like group was 78.4% and 45.1% （P = 0.005）, respectively. The estimated mean time of overall survival （OS） in the CHOPR-like group and CHOP- like group was 58.7 ± 2.8 and 36.4 ±3.4 months, respectively （P = 0.002）. The rates of CR and OR （overall remission） in CHOPR- like with IFN arm were 85.0% and 95.0%, and the rates of those in CHOPR-like without IFN arm were 74.2% and 87.0% （P 〉 0.05）. The estimated mean time of 4-year-PFS （progression- free survival） in CHOPR-like with IFN arm and in CHOPR-like without IFN arm was 62.9 ±3.0 months and 51.0 ± 4.6 months （P = 0.092）, respectively. In the CHOPR-like with IFN arm, no patient relapsed after achieving CR, while the estimated rate of 4-year- DFS （disease-free survival） in the patients who reached CR in the CHOPR-like without IFN arm was （63.4 ± 19.3）% （P = 0.061）. CONCLUSION Rituximab combined with CHOP-like chemotherapy improved the prognosis of DLBCL patients. The IFN may help to improve the quality and duration of response of DLBCL patients treated with rituximab and CHOP-like regimen.展开更多
目的:评估雾化吸入给药对重组人干扰素-α2b(rhIFN-α2b)生物活性和分子结构的影响。方法:采用病毒抑制法检测rhIFN-α2b的生物活性,通过比较雾化前后rhIFN-α2b生物活性的变化分析空气射流对其生物活性的影响。采用高效液相色谱(HPLC)...目的:评估雾化吸入给药对重组人干扰素-α2b(rhIFN-α2b)生物活性和分子结构的影响。方法:采用病毒抑制法检测rhIFN-α2b的生物活性,通过比较雾化前后rhIFN-α2b生物活性的变化分析空气射流对其生物活性的影响。采用高效液相色谱(HPLC)法和十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)法分析干扰素分子结构的改变。结果:雾化给药不会造成rhIFN-α2b蛋白质肽键断裂,但是空气射流会造成二硫键断裂,断裂比例与雾化前rhIFN-α2b浓度有关,600万IU/m L、300万IU/m L和100万IU/m L rhIFN-α2b雾化后纯度分别为82.9%、90.1%和94.9%。600万IU/m L rhIFN-α2b溶液雾化后17.1%的rhIFN-α2b分子出现二硫键的断裂,其中0.5%的rhIFN-α2b分子出现双二硫键断裂,雾化后喷雾壶内未完全汽化的剩余液中rhIFN-α2b的生物活性保留率为98.2%,雾化后收集的凝集液中rhIFN-α2b的生物活性保留率为96.1%。结论:rhIFN-α2b能以雾化状态稳定传输给药,生物活性基本保留。雾化后绝大部分rhIFN-α2b分子结构保持完整,少数分子出现单个或双二硫键断裂,为了尽量减少rhIFN-α2b分子的损耗,临床上雾化吸入rhIFN-α2b的浓度不应超过100万IU/m L。展开更多
目的观察重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊治疗宫颈高危型人乳头瘤病毒(high-risk human papillomavirus,HPV)持续感染的临床效果。方法将110例宫颈高危型HPV持续感染而液基细胞学检查阴性的患者随机分为两组,其中对照组(58例)...目的观察重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊治疗宫颈高危型人乳头瘤病毒(high-risk human papillomavirus,HPV)持续感染的临床效果。方法将110例宫颈高危型HPV持续感染而液基细胞学检查阴性的患者随机分为两组,其中对照组(58例)予以重组人干扰素α-2b凝胶治疗,观察组(52例)予以重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊治疗,两组患者均连续治疗3个月经周期。比较两组患者HPV转阴率及阴道微生态改善情况。结果观察组患者治疗总有效率(82.69%)高于对照组(63.79%),差异有统计学意义(χ^(2)=4.937,P=0.026)。治疗后,两组患者阴道微生态失调率均有所下降,且观察组改善情况更为显著(均P<0.05)。治疗后观察组患者阴道菌群密集度及多样性显著低于治疗前,其微生物功能指标优于对照组,乳杆菌定植率高于对照组,病原菌检出率低于对照组(均P<0.05)。结论在重组人干扰素α-2b凝胶治疗的基础上联合应用乳酸菌阴道胶囊能明显提高宫颈高危型HPV持续感染的转阴率,其中促进阴道微生态恢复平衡可能是其发挥作用的机制之一。展开更多
文摘Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B（CHB）. The objective of the present study was to compare the efficacy and safety of pegylated interferon（Peg-IFN） alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone（1.5 μg/kg once weekly） or Peg-IFN alpha-2b plus adefovir（10 mg daily） for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30（36.7%） patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31（25.8%） in the monotherapy group（P=0.36）. In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group（76.7% vs. 29.0%, P〈0.001）. Thyroid dysfunction was more frequent in the combination group than in the monotherapy group（P〈0.05）. In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function.
文摘OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin＇s lymphoma （DLBCL）.METHODS From January 2003 to July 2008, 51 patients received CHOP-like chemotherapy （cyclophosphamide 750 mg/m2, epirubicin 80 mg/m2, vindesine 2.8 mg/m2 on day 1, and prednisolone 100 mg/day on day 1 to day 5）. Thirty-one patients received CHOPR-like treatment （rituximab 375 mg/m2 1 day before CHOP-like chemotherapy）. Twenty patients received CHOP-like regimen in combination with peginterferon （pegIFN） （1μg/kg on day 5） and rituximab （on day 6）.RESULTS -The CR （complete remission） rate in the CHOPR-like （with or without pegIFN） group and in the CHOP-like group was 78.4% and 45.1% （P = 0.005）, respectively. The estimated mean time of overall survival （OS） in the CHOPR-like group and CHOP- like group was 58.7 ± 2.8 and 36.4 ±3.4 months, respectively （P = 0.002）. The rates of CR and OR （overall remission） in CHOPR- like with IFN arm were 85.0% and 95.0%, and the rates of those in CHOPR-like without IFN arm were 74.2% and 87.0% （P 〉 0.05）. The estimated mean time of 4-year-PFS （progression- free survival） in CHOPR-like with IFN arm and in CHOPR-like without IFN arm was 62.9 ±3.0 months and 51.0 ± 4.6 months （P = 0.092）, respectively. In the CHOPR-like with IFN arm, no patient relapsed after achieving CR, while the estimated rate of 4-year- DFS （disease-free survival） in the patients who reached CR in the CHOPR-like without IFN arm was （63.4 ± 19.3）% （P = 0.061）. CONCLUSION Rituximab combined with CHOP-like chemotherapy improved the prognosis of DLBCL patients. The IFN may help to improve the quality and duration of response of DLBCL patients treated with rituximab and CHOP-like regimen.
文摘目的:评估雾化吸入给药对重组人干扰素-α2b(rhIFN-α2b)生物活性和分子结构的影响。方法:采用病毒抑制法检测rhIFN-α2b的生物活性,通过比较雾化前后rhIFN-α2b生物活性的变化分析空气射流对其生物活性的影响。采用高效液相色谱(HPLC)法和十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)法分析干扰素分子结构的改变。结果:雾化给药不会造成rhIFN-α2b蛋白质肽键断裂,但是空气射流会造成二硫键断裂,断裂比例与雾化前rhIFN-α2b浓度有关,600万IU/m L、300万IU/m L和100万IU/m L rhIFN-α2b雾化后纯度分别为82.9%、90.1%和94.9%。600万IU/m L rhIFN-α2b溶液雾化后17.1%的rhIFN-α2b分子出现二硫键的断裂,其中0.5%的rhIFN-α2b分子出现双二硫键断裂,雾化后喷雾壶内未完全汽化的剩余液中rhIFN-α2b的生物活性保留率为98.2%,雾化后收集的凝集液中rhIFN-α2b的生物活性保留率为96.1%。结论:rhIFN-α2b能以雾化状态稳定传输给药,生物活性基本保留。雾化后绝大部分rhIFN-α2b分子结构保持完整,少数分子出现单个或双二硫键断裂,为了尽量减少rhIFN-α2b分子的损耗,临床上雾化吸入rhIFN-α2b的浓度不应超过100万IU/m L。
文摘目的观察重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊治疗宫颈高危型人乳头瘤病毒(high-risk human papillomavirus,HPV)持续感染的临床效果。方法将110例宫颈高危型HPV持续感染而液基细胞学检查阴性的患者随机分为两组,其中对照组(58例)予以重组人干扰素α-2b凝胶治疗,观察组(52例)予以重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊治疗,两组患者均连续治疗3个月经周期。比较两组患者HPV转阴率及阴道微生态改善情况。结果观察组患者治疗总有效率(82.69%)高于对照组(63.79%),差异有统计学意义(χ^(2)=4.937,P=0.026)。治疗后,两组患者阴道微生态失调率均有所下降,且观察组改善情况更为显著(均P<0.05)。治疗后观察组患者阴道菌群密集度及多样性显著低于治疗前,其微生物功能指标优于对照组,乳杆菌定植率高于对照组,病原菌检出率低于对照组(均P<0.05)。结论在重组人干扰素α-2b凝胶治疗的基础上联合应用乳酸菌阴道胶囊能明显提高宫颈高危型HPV持续感染的转阴率,其中促进阴道微生态恢复平衡可能是其发挥作用的机制之一。
